ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma

ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450), offering novel perspectives and important insights into immunotherapy combinations for relapsed/refractory lymphoma. Hematology Frontier invited Dr. Cai to share the clinical significance and key findings of her team’s research.
ASH 2024 | Dr. Wei Xu: Redefining CNS Involvement Evaluation and Prophylactic Strategies with CSF-ctDNA Testing

ASH 2024 | Dr. Wei Xu: Redefining CNS Involvement Evaluation and Prophylactic Strategies with CSF-ctDNA Testing

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort. This study, selected for oral presentation (O576), not only deepens our understanding of CNS involvement in DLBCL but also offers innovative perspectives for clinical management and treatment strategies. Hematology Frontier invited Dr. Xu to share insights into the significance of CSF-ctDNA testing, its potential role in future DLBCL clinical practice, and its far-reaching impact on patient treatment strategies.
ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options

ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions (P1676, P3113, P4442). Hematology Frontier invited Professor Huang to share their insights and the clinical implications of these studies directly from the ASH venue.
SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment

SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment

In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases, no studies have explored these strategies in real-world settings.
SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients

SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients

The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on GQ1005, a highly promising HER2 antibody-drug conjugate (ADC). The study’s evaluation of GQ1005’s efficacy and safety in HER2-positive metastatic breast cancer (MBC) patients drew significant attention, leading to vibrant discussions among experts. Dr. Wang provides an in-depth interpretation of this important research.
Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk

Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk

From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many noteworthy contributions, a study by Dr. Yunjian Liu's team from The Fourth Hospital of Hebei Medical University stood out. Their research focused on the prognostic value of ctDNA monitoring in breast cancer patients undergoing neoadjuvant therapy and was presented as a poster (Abstract No. P3-05-22). The study highlights how personalized ctDNA testing can dynamically monitor minimal residual disease (MRD), predict treatment efficacy and recurrence risk, and provide valuable insights for clinical decision-making. Oncology Frontier interviewed Professor Liu onsite for an in-depth discussion.
SABCS 2024 | Prof. Yongmei Yin Connects with Prof. Qiang Liu: Key Findings from the Conference’s Final Day on Immunotherapy Advances

SABCS 2024 | Prof. Yongmei Yin Connects with Prof. Qiang Liu: Key Findings from the Conference’s Final Day on Immunotherapy Advances

The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest research, clinical practices, and technological innovations in breast cancer. In this special installment of the “Highlights Series,” hosted by Prof. Yongmei Yin of Jiangsu Provincial People’s Hospital, Prof. Qiang Liu from the Sun Yat-sen Memorial Hospital joins us live from SABCS to present significant immunotherapy findings unveiled on the final day of the conference (December 13). These include updates on the ZEST, CamRelief, NSABP B-59/GBG-96-GeparDouze, A-BRAVE, and BreastImmune-03 studies for triple-negative breast cancer (TNBC), as well as insights into HER2-positive breast cancer from the NRG-BR004 and neoHIP trials.